Management of Mild vs Moderate Hypertension
For moderate hypertension (≥140/90 mm Hg), start antihypertensive medications immediately regardless of cardiovascular risk; for mild hypertension (130-139/80-89 mm Hg), the decision to start medications depends on the presence of clinical CVD, diabetes, CKD, or 10-year CVD risk ≥7.5% using PREVENT—if these are absent, attempt lifestyle modification for 3-6 months first before initiating medications. 1
Blood Pressure Classification Framework
The 2025 AHA/ACC guidelines define hypertension stages as:
- Stage 1 (Mild) Hypertension: 130-139 mm Hg systolic OR 80-89 mm Hg diastolic
- Stage 2 (Moderate) Hypertension: ≥140 mm Hg systolic OR ≥90 mm Hg diastolic 2
Treatment Algorithm by Blood Pressure Level and Risk
Moderate Hypertension (≥140/90 mm Hg)
Immediate medication initiation is mandatory for all adults with average BP ≥140/90 mm Hg, as this threshold has Class 1, Level A evidence for reducing cardiovascular events and total mortality. 1 This applies universally regardless of:
- Presence or absence of CVD
- Diabetes status
- CKD status
- Calculated CVD risk
The evidence from 48 RCTs involving 344,716 participants demonstrates consistent relative benefit with each 5 mm Hg systolic reduction, with similar benefit in those with CVD (RR: 0.89) and without CVD (RR: 0.91). 1
For stage 2 hypertension specifically, initiate 2 first-line agents of different classes in a single-pill fixed-dose combination rather than separate pills to improve adherence and reduce time to BP control. 2
Mild Hypertension (130-139/80-89 mm Hg)
The approach is risk-stratified:
High-Risk Patients (Start Medications Immediately at 130/80 mm Hg)
Initiate antihypertensive medications immediately if the patient has ANY of the following:
- Clinical CVD (prior MI, stroke, heart failure, etc.) 1
- Diabetes mellitus 1
- Chronic kidney disease 1
- 10-year CVD risk ≥7.5% based on PREVENT calculator 1
This recommendation carries Class 1, Level A evidence for patients with clinical CVD and Class 1, Level A evidence for those with diabetes, CKD, or elevated CVD risk.
Lower-Risk Patients (Trial Lifestyle Modification First)
For patients with BP 130-139/80-89 mm Hg AND 10-year CVD risk <7.5% by PREVENT AND no diabetes, CKD, or clinical CVD:
Implement intensive lifestyle interventions for 3-6 months including:
- Weight management to achieve/maintain healthy BMI
- DASH eating pattern
- Sodium reduction
- Increased dietary potassium
- Moderate physical activity program
- Stress management
- Alcohol reduction/elimination 2
Reassess BP after 3-6 months
If BP remains ≥130/80 mm Hg after lifestyle trial, initiate medications to prevent target organ damage and mitigate further BP rise (Class 1, Level B-R evidence) 1
Critical Pitfalls to Avoid
Do not delay treatment in moderate hypertension (≥140/90 mm Hg) for a lifestyle modification trial—the evidence is unequivocal that immediate medication initiation reduces morbidity and mortality at this threshold. 1
Do not use cuffless devices or smartwatches for BP measurements to guide treatment decisions, as they lack precision and reliability. 2
Do not send patients with severe hypertension (>180/120 mm Hg) without acute target organ damage to the emergency department—manage them in the outpatient setting with timely initiation, reinstitution, or intensification of oral medications. 2
Overarching Treatment Target
The BP treatment goal is <130/80 mm Hg for all adults with hypertension, regardless of initial severity or risk category. 2 This unified target simplifies management and is supported by the totality of evidence showing cardiovascular benefit with lower achieved BP levels.